During the first two and a half years of the project, we have focused on CRISPR interference (CRISPRi) screening in clinical Enterobacterales to understand the biology and persistence of carbapenem-resistance plasmids.
First, we performed plasmid-wide CRISPRi screens to investigate pOXA-48, a highly disseminated plasmid that confers resistance to carbapenems—critical last-line antibiotics used to treat severe infections—in multidrug-resistant Enterobacterales. By analysing 13 clinical strains, we found that the biological effects imposed by this plasmid are remarkably consistent across diverse bacterial backgrounds. Our results demonstrate that the resistance gene blaOXA-48, which encodes the carbapenem-degrading enzyme, is also the main determinant of the fitness burden that the plasmid imposes on its host. Overall, this work provides new insight into how carbapenem-resistant bacteria survive and spread, and demonstrates that CRISPRi screening is a powerful approach for uncovering hidden vulnerabilities in antibiotic resistance mechanisms. These findings were published in Nature Communications (2025).
Second, we initiated genome-wide CRISPRi screens in a collection of clinical Klebsiella pneumoniae strains. We constructed isogenic variants with or without two carbapenemase-encoding plasmids, pOXA-48 and pVIM-1, and completed genome-wide CRISPRi screens across all strains. We have recently obtained the sequencing data and will now compare plasmid-carrying and plasmid-free pairs to identify plasmid–genome genetic interactions. Over the coming year, we will analyse and validate these interactions and extend our screens to systems of greater ecological complexity.
In parallel, using a transcriptomic approach, we examined how pOXA-48 interacts with diverse multidrug-resistant Enterobacterales. Although the plasmid often alters gene expression in a strain-specific manner, it consistently activates a small chromosomal gene cluster in certain species, including Klebsiella and Citrobacter. These genes are widely distributed among related bacteria, suggesting historical horizontal transfer. Through genetic engineering, gene expression analyses, and targeted gene silencing, we identified a plasmid-encoded regulatory protein that functions as a molecular “switch,” enabling the plasmid to modulate host gene expression. Activation of these chromosomal genes provides a growth advantage to bacteria carrying pOXA-48, promoting their survival and dissemination.
These findings reveal a previously unrecognised cooperation between resistance plasmids and bacterial chromosomes, suggesting that such interactions facilitate the persistence and spread of carbapenem resistance in clinical environments. This work was published in Nature Communications (2024). As continuation of this study, and in collaboration with the lab of Didier Mazel (Pasteur Institute, Paris), we developed a new new eco-evo-informed treatment targeting pOXA-48-carrying enterobacteria. Specifically, we used engineered toxin–intein modules, programmable cassettes that restrict toxic activity to specific regulatory contexts, under the control of the pOXA-48-encoded transcriptional regulator. Integration of the anti-pOXA-48 module into mobilizable and conjugative vectors enabled effective suppression of resistance plasmid spread in complex microbial communities. This study is under second round of revision in Nucleic Acids Research.
In parallel, and in continuation of the work started during my ERC StG PLASREVOLUTION, we have discovered that plasmid-encoded IS (insertion sequence) elements play a key role in the evolution fo AMR in clinical Enterobacterales. This work was published in Nature Microbiology (2026)
We have also collaborate with the research group of JR Penades (Imperial College), describing how limits to plasmid transmission may be beneficial for bacterial populations. This work was published in Cell Reports (2025).